Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb;3(1):39-42.
doi: 10.1177/2397198317751864. Epub 2018 Apr 4.

Anticoagulant treatment in patients with pulmonary arterial hypertension associated with systemic sclerosis: More shadows than lights

Massimiliano Palazzini  1 , Alessandra Manes  1 , Enrico Gotti  1 , Fabio Dardi  1 , Andrea Rinaldi  1 , Nazzareno Galiè  1
Affiliations
Review

Anticoagulant treatment in patients with pulmonary arterial hypertension associated with systemic sclerosis: More shadows than lights

Massimiliano Palazzini et al. J Scleroderma Relat Disord. 2018 Feb.

Abstract

Pulmonary arterial hypertension is a chronic and progressive disease characterized by elevated pulmonary artery pressure and pulmonary vascular resistance leading to heart failure and premature death. Pulmonary arterial hypertension is characterized by proliferative and obstructive lesions in the distal pulmonary arteries and some descriptions include also thrombotic lesions. Despite this, in an era when multiple effective pulmonary arterial hypertension therapies are available, the role of anticoagulation in the treatment of pulmonary arterial hypertension remains uncertain. In particular, anticoagulant treatment in pulmonary arterial hypertension associated with connective tissue disease seems to be associated with unfavorable risk to benefit ratio due to an increased rate of bleeding from the gastrointestinal tract. However, anticoagulation may be required in conditions with increased thrombophilia like in the presence of lupus anticoagulant phenomenon or in the presence of anticardiolipin antibodies.

Keywords: Anticoagulation; Pulmonary arterial hypertension; Systemic sclerosis; Therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Financial support: No grants or funding have been received for this study. Conflict of interest: None of the authors has financial interest related to this study to disclose.

References

    1. Galiè N, Humbert M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. - PubMed
    1. Dorfmüller P, Humbert M. Progress in pulmonary arterial hypertension pathology: relighting a torch inside the tunnel. Am J Respir Crit Care Med. 2012;186(3):210-212. - PubMed
    1. Fuster V, Steele PM, Edwards WD, et al. . Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70(4):580-87. - PubMed
    1. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest. 2006;130(2):545-552. - PubMed
    1. Humbert M, Sitbon O, Chaouat A, et al. . Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-1030. - PubMed